other

【Product name】Alfuzosin

[English common name]Hydrochloride

[Chinese common name]Alfuzolium hydrochloride

[English name]

[Chinese other name]Alfazosin

[indications]
Alfuzosin hydrochloride tablets: used to alleviate the symptoms of benign prostatic hyperplasia.
Alfuzosin hydrochloride sustained-release tablets: functional symptoms of benign prostatic hyperplasia.

【Dosage】
Alfuzosin hydrochloride tablets: Oral, it is recommended to take the first dose before going to bed.
Usually, the usual dose for adults is 1 tablet (2.5 mg) once a day, 3 times a day, and the starting dose for elderly patients is 1 tablet (2.5 mg) in the morning and evening, up to 4 tablets (10 mg) per day.
Patients with impaired renal function: The starting dose should be 1 tablet (2.5 mg) once a day, twice a day, and then adjusted according to clinical response.
Patients with mild to moderate hepatic impairment: The initial dose should be 1 tablet (2.5 mg) once a day, and then increased to 1 tablet once a day according to the clinical response.
Alfuzosin hydrochloride sustained-release tablets: recommended dose, 1 tablet (10 mg) long-acting sustained-release tablets per day, taken immediately after dinner. The tablet needs to be swallowed whole and cannot be chewed. Or as directed by a doctor

[Storage]
Alfuzosin hydrochloride tablets: sealed and stored.
Alfuzosin hydrochloride sustained-release tablets: no special requirements.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Mepact

[English common name]Mifamurtide

[Chinese common name]Mirafarin injection

[English name]L-MTP-PE

[Chinese other name]

[Indications] Treatment of non-metastatic high-grade excision after complete resection of macroscopic surgery in children, adolescents, and young adults. The drug was evaluated in conjunction with more "post-chemotherapy. Safety and efficacy have been established at the age of between 2 and 30 years of age".

[Usage and Dosage] Treatment should be initiated and supervised by experienced specialists in the diagnosis and treatment of osteosarcoma. The recommended dose for all patients with mifamurtide and the '2 mg/m2 diarea body surface.
The agents must be adjuvanted with somministratocome as follows: at a distance of 12 weeks from each other at least 3 days per week, then transferred to treatment once a week for another 24 weeks for a total of 48 infusions for 36 weeks.
Pediatric patients: Safety and effectiveness have been established from two-year-old children. Use did not qualify with "medicinal use in the following children due to lack of safety and effectiveness didate 2 years.
Elderly patients: Osteosarcoma studies include patients 65 years of age and older. In a randomized phase III study, only patients were "up to 30 years old."
Therefore, there is not enough data to recommend middle-aged patients "more than 30 years of use of the product. The patient's kidney or liver function damage: the characteristics of the patient's kidney or liver function damage farmacocinetichedi mifamurtide has not been formally studied. It is recommended to be careful about conquesti patients because there is no Any information on the amount. Continuous monitoring of renal and liver function is recommended if the drug is used beyond the completion of chemotherapy until the treatment is completed.
Mododi Management: The product should be reconstituted, using a filter, and provided for further dilution filtration prior to administration. Reconstitute the suspension for infusion, filter, and 'opaque liposome suspension evenly, white to off-white, no visible particles and free foam and lipid lumps.
Once reconstituted, it is further diluted using a filter provided, and the drug is administered by intravenous infusion within one hour. The drug should not be administered as a bolus injection.

[Storage] Store in the refrigerator (2 degrees Celsius – 8 degrees Celsius). Do not freeze. Keep the vial of the outer box to protect the medicinaledalla light.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Spherusol

[English common name]Coccidioides immitis

[Chinese common name]Coccidioides

[English name]

[Chinese other name]

[Indications] Detection of delayed-type hypersensitivity after infection with Coccidioides in patients with a history of pulmonary sporulation from 18 to 64 years old.

[Usage and Dosage] Spherusol is a transparent, colorless sterile solution for intradermal administration.
In the case where the solution and container permit, the particulate matter and discoloration of the parenteral drug product should be visually inspected prior to administration. If any of these conditions are present, the skin test antigen should not be administered.
Spherusol® was administered by intradermal injection at a dose of 0.1 mL using a tuberculin syringe (0.5 or 1.0 mL) and a 1⁄2 inch 26-27 gauge needle on the volar surface of the forearm. The needle should be inserted into the skin with a slanted face up at an angle of 15-20 degrees. Intradermal injection of 0.1 mL of Spherusol produces bubbles of 5-10 mm in diameter at the injection site.
The induration at the injection site should be evaluated 48 hours (± 4 hours) after administration. The response to the skin test should be measured by taking the average of the orthogonal diameters of the induration region. An average induration ≥ 5 mm is considered to be a positive delayed hypersensitivity reaction to Spherusol. Repeated administration of Spherusol(R) has not been evaluated.
Spherusol® is an intradermal injection provided in a 1 mL multi-dose vial. Each 0.1 mL dose contained 1.27 mcg of pellet-derived Coccidioides immitis antigen.

[Storage] Refrigerated at 2° to 8°C (35° to 46°F). Do not freeze. Discard if frozen. Do not use after the expiration date.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

【Product name】Dysport

[English common name]Abobotulinumtoxin A

[Chinese common name]Botulinum toxin A

[English name]

[Chinese other name]

[Indications] Eyelids, hemifacial spasms and related disorders of dystonia.

[Usage and Dosage] The recommended dose of this product should not be interchanged with the dose of other Clostridium botulinum toxin preparations. This product must be used by a physician with appropriate qualifications and experience in treatment, and with appropriate equipment. The optimal effective dose and the optimal number of injection sites per muscle have not yet been established, so individual treatment regimens should be developed by the physician and the optimal dose should be determined by titration. Ailigen will assist in the training of this product injection technology. The recommended dose range for each injection site is 0.05-0.1 ml (eyelid, hemifacial spasm). See the following dilution table. Injection of this product with a sterile, 27-30/0.40-0.30mm needle does not necessarily require EMG monitoring. The recommended initial injection dose for the lateral part of the medial and lateral parts of the upper orbital iliac muscle of the upper eyelid iliac muscle is 1.25-2.5 U. If the eyebrows, the lateral aspect of the orbicularis and the upper facial area affect visual acuity, the injection site should also be increased at the corresponding site. Avoiding injections close to the upper eyelid side can reduce complications of drooping eyelids. Avoid the injection of the inside of the lower eyelid to reduce the spread of the oblique muscle, which can reduce the complications of double vision. The lower icon shows the injection reference site: it takes effect within three days after the general injection and reaches a peak in 1-2 weeks. Each treatment lasts for approximately 3 months and can be repeated as needed. When repeating treatment, if the initial therapeutic dose is considered insufficient, the injected dose can be increased or even doubled. However, if an injection site dose exceeds 5.0 U, there will be no better effect. The initial therapeutic dose per eye should not exceed 25U. In general, treatment frequencies greater than once every 3 months are not beneficial to the patient. When treating eyelids, the total dose per 12 weeks should not exceed 100U. Hemifacial spasm and VII pairs of patients with abnormal brain function, treatment of patients with unilateral orbital, and other affected facial muscles can be injected as needed. If the first treatment fails, ie one month after the injection, there is no significant clinical improvement compared to before treatment, the following measures should be taken: • Clinical validation, including specialists performing an EMG examination of the blockade of injected muscle; • Analysis failure Causes such as: improper selection of injected muscles, insufficient injection dose, lack of injection technique, occurrence of fixed muscle contracture, antagonism of muscle weakness, neutralization of toxin antibody formation, etc.; • Re-evaluation of treatment with Clostridium botulinum toxin type A; • If the first treatment is not effective, the following measures can be taken for the second treatment:
(1) Analyze the cause of the first treatment failure and adjust the dose;
(2) Injection under EMG monitoring;
(3) There is a three-month interval between the two treatments. If the reinjection treatment fails or is not effective, consider replacing the treatment. How to use, handle and dispose of this product: It is recommended to carry out the dilution operation and the preparation of the syringe on the paper towel with plastic liner to prevent the liquid from splashing. The product was diluted with sterile, preservative-free saline (0.9% sodium chloride for injection). Draw the appropriate amount of diluent with a syringe (see the dilution table below). Since the product will be denatured by the vibration of bubbles or similar forces, the diluent should be gently pushed into the bottle. If there is no vacuum suction in the bottle, the bottle should be discarded. After preparation, this product should be a clear liquid with no color to slightly yellow and no impurities. Before using the preparation solution, visually check the clarity and impurities. The preparation solution should be stored in the refrigerator (2 ° C - 8 ° C) for up to 4 hours. This product can only be used in a single use, and the remaining solution should be discarded. For safety reasons, unused vials should be filled with a small amount of water and then autoclaved; all used vials, syringes, and spilled liquids should be autoclaved or 0.5% hypochlorous acid. The salt solution inactivated the residue of the product for 5 minutes.

[Storage] Store at 2oC~8oC in cold storage or below -5oC. After preparation: Store at 2oC~8oC in cold storage and use within 4 hours. Container: A 10 ml capacity type I colorless glass bottle with a rubber stopper and sealed with aluminum foil.

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.